Regulated information

2024 half-year Results

Sales: €264m (+3.2% as reported)
Essentials products sales: €160m (+6.0% of Group sales)
Net income - Group share: €24m (9.0% of sales)
EBITDA*: €45m (17% of sales)
Cash-flow generation: €27m

Monthly information regarding the total number of voting rights – August 2024

Monthly information regarding the total number of voting rights – July 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »
 

Monthly information regarding the total number of voting rights – June 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »
 

Monthly information regarding the total number of voting rights – May 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthy information regarding the total number of voting rights and shares making of the share capital - April 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

Monthly information regarding the total number of voting rights – March 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m